The US drug authority FDA wants to primarily check the GSK drug Potidacin in order to determine whether it is suitable for the treatment of uncomplicated urogenital gonorrhea.
In the event of admission, Potidacin allows oral treatment of US patients who are currently dependent on injectable treatments, GSK announced on Monday and said there were considerable need for new antibiotics for the sexually transmitted infectious disease, which is also called ripper.
The application of the company listed in London to the FDA includes positive phase III data from the EAGLE 1 study, according to GSK.
According to the US Centers for Disease Control and Prevention, more than 600,000 Gonorrhea cases were reported in the United States in 2023. In the United States there is no license for a vaccine to prevent this disease.
The FDA will probably announce its decision in December, added GSK.
The GSK share in London temporarily gains 0.82 percent to 14.07 GBP.
DJG/DJN/Rio/Sha
Dow Jones
By the way: GSK and other US shares are even tradable at Finance.net Zero until 11 p.m. (without order fees, plus spreads). Open Depot now for free And secure new customer bonus!
Selected leverage products on GSK
With knock-outs, speculative investors can participate disproportionately in price movements. Simply choose the desired lever and we will show you suitable open-end products on GSK
The lever must be between 2 and 20
Advertising